At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Glucose-dependent Insulinotropic Polypeptide (GIP) (drug), Cagrilintide (drug), Placebo GIP (drug)
- How long the study runs
- Study runs about 11 months (dates as stated)
- About the drug or intervention
- Glucose-dependent Insulinotropic Polypeptide (GIP) — drug: Participants will receive GIP subcutaneously. · Cagrilintide — drug: Participants will receive Cagrilintide subcutaneously. · Placebo GIP — drug: Participants will receive placebo matched to GIP subcutaneously.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 64 Years
- Who
- Female
- Number of participants
- 100
- Started
- 2026-02-09
- Last checked
- 2026-04
Plain English Summary
What is this study?
- • Testing a new treatment for overweight
- • Phase1 - 100 participants
- • This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone
Who can take part?
- • Ages 18 Years to 64 Years
- • Diagnosed with overweight
- • Female only
Where?
- • Harrow - Parexel Research Unit
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide and NNC0480-0389. In the other period, participants will get cagrilintide together with a placebo version of NNC0480-0389.The placebo looks like the real treatment but does not have any active medicine in it. Cagrilintide and NNC0480-0389 is a new medicine being tested to help people with type 2 diabetes and/or overweight or obesity. The trial medicines is not yet approved for use outside of clinical trials. Participants will receive the trial medicines the way the trial doctor has described. The study will last for about 4.5 months.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 64 Years
- Who can join: Female only
What the study is looking for
- ✓Female at birth.
- ✓Age 18-64 years (both inclusive) at the time of signing the agreement to take part.
- ✓Body mass index (BMI) between 27.0 kilograms per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening.
- ✓Overweight should be due to excess adipose tissue, as judged by the investigator.
- ✓Considered eligible with suitable veins for cannulation or repeated venepuncture, as judged by the investigator.
Who cannot take part
- ✗Known or suspected hypersensitivity to study intervention(s) or related products.
- ✗Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using...
- ✗Current participation (i.e., dosing) in any other interventional clinical study within 90 days before screening.
- ✗Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
- ✗Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before...
See the full criteria
Where Is This Study? (1 UK site)
Parexel Research Unit
Harrow HA1 3UJ, United Kingdom
How to Get in Touch
Novo Nordisk
Sponsor contactCONTACT